STK11 and non-small cell lung carcinoma: Overall, the available clinical evidence, and in data from large observational real-world genomic study and the two subgroup analyses from the phase 3 MYSTIC and KEYNOTE-189 trials, point to LKB1 inactivation as a negative prognostic factor, rather than a predictor of poor benefit from immunotherapy, in patients with advanced NSCLC.